Cargando…

Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes

BACKGROUND: Statins are the primary drug used to reduce morbidity and mortality for cardiovascular disease. However, many type II diabetes mellitus (T2DM) patients who are currently not on a statin would otherwise qualify. Therefore, we investigated the proportion of T2DM patients on a statin compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Keegan, Kopel, Jonathan, Diab, Mousab, Babb, Franklyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Greater Baltimore Medical Center 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593177/
https://www.ncbi.nlm.nih.gov/pubmed/37877046
http://dx.doi.org/10.55729/2000-9666.1162
_version_ 1785124400949886976
author Dunn, Keegan
Kopel, Jonathan
Diab, Mousab
Babb, Franklyn
author_facet Dunn, Keegan
Kopel, Jonathan
Diab, Mousab
Babb, Franklyn
author_sort Dunn, Keegan
collection PubMed
description BACKGROUND: Statins are the primary drug used to reduce morbidity and mortality for cardiovascular disease. However, many type II diabetes mellitus (T2DM) patients who are currently not on a statin would otherwise qualify. Therefore, we investigated the proportion of T2DM patients on a statin compared to the total number of T2DM patients eligible to be on a statin. We also examined potential barriers that prevent T2DM patients from being prescribed statins by physicians. METHODS: A retrospective chart study on family medicine patients was collected data on age, race, cholesterol readings, blood pressure, and whether the patient was on blood pressure medications, aspirin, and/or a statin. The information gathered was used to determine the patients’ 10-year risk of cardiovascular disease. A survey was given to residents and faculty to assess the cost, side effects, and other behavioral factors had on a patients’ choice to be on a statin. RESULTS: Among the 706 T2DM patients, we found that a large proportion (75.2%) were both eligible and prescribed a statin according to the American Heart Association Guidelines. In addition, over 58% of the patients had a 0%–25% 10-year risk of cardiovascular disease risk. Among the 14 family medicine physicians surveyed, the fear of or history of side effects with statin medications were the greatest barriers to starting statins. CONCLUSION: The large proportion of family medicine patients that were eligible were prescribed a statin. According to the survey, physicians Believed that the greatest barrier for a patient starting on a statin is the fear of or history of side effects with statin medications.
format Online
Article
Text
id pubmed-10593177
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Greater Baltimore Medical Center
record_format MEDLINE/PubMed
spelling pubmed-105931772023-10-24 Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes Dunn, Keegan Kopel, Jonathan Diab, Mousab Babb, Franklyn J Community Hosp Intern Med Perspect Editorial BACKGROUND: Statins are the primary drug used to reduce morbidity and mortality for cardiovascular disease. However, many type II diabetes mellitus (T2DM) patients who are currently not on a statin would otherwise qualify. Therefore, we investigated the proportion of T2DM patients on a statin compared to the total number of T2DM patients eligible to be on a statin. We also examined potential barriers that prevent T2DM patients from being prescribed statins by physicians. METHODS: A retrospective chart study on family medicine patients was collected data on age, race, cholesterol readings, blood pressure, and whether the patient was on blood pressure medications, aspirin, and/or a statin. The information gathered was used to determine the patients’ 10-year risk of cardiovascular disease. A survey was given to residents and faculty to assess the cost, side effects, and other behavioral factors had on a patients’ choice to be on a statin. RESULTS: Among the 706 T2DM patients, we found that a large proportion (75.2%) were both eligible and prescribed a statin according to the American Heart Association Guidelines. In addition, over 58% of the patients had a 0%–25% 10-year risk of cardiovascular disease risk. Among the 14 family medicine physicians surveyed, the fear of or history of side effects with statin medications were the greatest barriers to starting statins. CONCLUSION: The large proportion of family medicine patients that were eligible were prescribed a statin. According to the survey, physicians Believed that the greatest barrier for a patient starting on a statin is the fear of or history of side effects with statin medications. Greater Baltimore Medical Center 2023-05-08 /pmc/articles/PMC10593177/ /pubmed/37877046 http://dx.doi.org/10.55729/2000-9666.1162 Text en © 2023 Greater Baltimore Medical Center https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ).
spellingShingle Editorial
Dunn, Keegan
Kopel, Jonathan
Diab, Mousab
Babb, Franklyn
Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes
title Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes
title_full Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes
title_fullStr Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes
title_full_unstemmed Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes
title_short Analyzing and Improving the Utilization of Statin Drugs in Family Medicine Patients with Type II Diabetes
title_sort analyzing and improving the utilization of statin drugs in family medicine patients with type ii diabetes
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593177/
https://www.ncbi.nlm.nih.gov/pubmed/37877046
http://dx.doi.org/10.55729/2000-9666.1162
work_keys_str_mv AT dunnkeegan analyzingandimprovingtheutilizationofstatindrugsinfamilymedicinepatientswithtypeiidiabetes
AT kopeljonathan analyzingandimprovingtheutilizationofstatindrugsinfamilymedicinepatientswithtypeiidiabetes
AT diabmousab analyzingandimprovingtheutilizationofstatindrugsinfamilymedicinepatientswithtypeiidiabetes
AT babbfranklyn analyzingandimprovingtheutilizationofstatindrugsinfamilymedicinepatientswithtypeiidiabetes